EGF and breast adenocarcinoma: The wild‐type p53‐expressing MCF‐7 epithelial cell line, a model of luminal breast adenocarcinoma, was selected for in vitro drug treatment and exposed for 48 h to three classes of bioactive compounds: EGF, nocodazole, and etoposide.